Leveraging the Healthy China 2030 strategy, national reforms in drug and medical device evaluation and approval, as well as the policy benefits of the Guangdong-Hong Kong-Macao Greater Bay Area, China's innovative pharmaceutical and medical device industry is entering a new phase characterized by accelerated R&D, expedited market access, and enhanced application quality. The 2026 Guangzhou Medical and Health Industry Expo, organized by the People's Government of Guangzhou Municipality and coordinated by the Guangzhou Municipal Health Commission and the Guangzhou Collaboration Office, will grandly open from August 21 to 23 at Zone B of the Canton Fair Complex. Under the core theme "Linking the Bay Area with the World • Innovation-Driven Health," the expo adopts a comprehensive exhibition system covering the entire industrial chain (3+8+X). Its flagship Innovation Pharmaceuticals and Medical Devices Zone integrates policy interpretation, achievement display, supply-demand matching, technology commercialization, and academic exchange, serving as a pivotal hub connecting global pharmaceutical and medical device innovation resources with the domestic clinical market.

With the support of comprehensive policies, a high-quality ecosystem for innovative development has been established.

Leveraging policy support at the national, Greater Bay Area, and Guangzhou levels, the exhibition area demonstrates distinct advantages and comprehensively facilitates the implementation of pharmaceutical and medical device innovations.

At the national level, regulatory reforms for pharmaceuticals and medical devices have been continuously deepened. Mechanisms such as priority review, conditional approval, and breakthrough therapy have been implemented to accelerate the market launch of innovative products. Coupled with a diversified medical insurance payment system, these measures have effectively addressed key challenges in the industry, including pricing difficulties, access barriers, and slow implementation.

Guangzhou has introduced a specialized support policy for the application of innovative pharmaceuticals and medical devices, leveraging measures such as real-world studies, green channels for hospital admission, and clinical demonstration applications to establish a localized innovation closed-loop system covering "research and development – trials – clinical implementation – promotion," thereby accelerating the rapid translation of innovative achievements into practice.

Leveraging the distinctive policies of the Greater Bay Area's Hong Kong and Macao Medicines and Medical Devices Access Program, and supported by legal frameworks and resources from 71 designated medical institutions, we have established a cross-border innovation pathway encompassing "overseas approval – rapid market access – clinical application – iterative improvement," providing a pioneering platform for cutting-edge international pharmaceuticals and medical devices to enter the mainland market.

A collection of groundbreaking achievements provides a comprehensive showcase of the

 industry's innovative capabilities.

As one of the key exhibition areas in the "Advanced Technologies and Future Medicine" pavilion at this year's Medical Expo, the Innovative Pharmaceuticals and Medical Devices Zone focuses on addressing clinical needs and promoting import substitution, bringing together leading domestic and international enterprises along with cutting-edge technologies. The exhibits cover the entire pharmaceutical and healthcare industry chain.

Innovative Drug Sector

The exhibition comprehensively showcases products listed in Guangzhou's Catalog of Innovative Pharmaceuticals and Medical Devices, new drugs approved under the Hong Kong and Macao Drug and Medical Device Access Program, internationally advanced innovative pharmaceuticals and medical devices, as well as novel vaccines. It focuses on high-end fields such as major diseases, rare diseases, and public health emergencies, displaying a range of high-quality pharmaceuticals that are feasible for implementation, translation, and application.

High-end Medical Device Sector

The exhibition features medical devices approved for use in Hong Kong and Macau, internationally advanced diagnostic and therapeutic equipment, and high-end innovative consumables, focusing on emerging fields such as precision medicine, minimally invasive surgery, and intelligent diagnostics. It serves as a pivotal platform for showcasing and facilitating exchanges regarding the localization of foreign medical devices and the substitution of imported products with domestically developed alternatives.

The exhibition area has attracted a large number of renowned pharmaceutical companies to establish their presence early, featuring a robust lineup of brands. These include global biopharmaceutical firms such as BeiGene, CanSino Biologics, and Hengrui Pharmaceuticals; leading domestic pharmaceutical companies like Zhengda Tianqing, Yipinhong, and Yinuo Pharmaceuticals; as well as industry leaders in diagnostics and medical devices including Huayinkang, Medtronic, and Shuimu Medical, collectively forming a strong industry brand matrix.

These diverse, high-end events create a comprehensive closed-loop system that integrates industry, academia, research, and practical application.

The exhibition is complemented by over 20 high-level parallel events covering all key areas including industry launches, academic seminars, cross-border collaboration, technology commercialization, centralized procurement coordination, and investment financing, providing comprehensive solutions to corporate development challenges. Key activities include: the launch ceremony of the Medical Expo with its "Innovation-Driven Health" thematic event; the Real-World Study Exchange Conference for Innovative Drugs and Medical Devices; the Frontier Technologies and Commercialization Forum for Medical Devices; the Cross-Border Medical Cooperation Meeting between Hong Kong and Macao for Pharmaceuticals and Medical Devices; the Release Event on Centralized Procurement Needs for Medical Institutions; and the Private Investment Summit on Pharmaceutical and Medical Device Innovation.

During the exhibition period, a specialized and refined supply-demand matchmaking event between hospitals and enterprises will be organized, featuring dedicated sessions on innovative pharmaceuticals, medical devices and consumables, smart healthcare, and traditional Chinese medicine-based health solutions. The event will bring together department heads, clinical experts, and procurement managers from tertiary hospitals across the city to engage in face-to-face discussions with corporate R&D and marketing teams, aiming to precisely align clinical needs with product resources, break down information barriers, and accelerate the clinical implementation of products.

The core value becomes evident as it provides comprehensive empowerment for the development of the entire industry.

01 Direct policy support to reduce entry barriers

By integrating policy resources at the national, Greater Bay Area, and Guangzhou levels, we provide on-site professional policy interpretation, market access guidance, and project application consultation to accelerate the review process, hospital approval, and clinical deployment of innovative products.

02 Full-chain aggregation for precise matching

By integrating resources across the entire industry chain—including R&D, production, clinical applications, capital, and government support—and connecting with decision-makers at over 500 medical institutions, the company significantly reduces costs associated with customer acquisition, collaboration, and commercialization.

03 Authoritative endorsement – amplifying brand visibility

Leveraging the government-backed official authority, combined with four-tier museum tours and multi-channel media coverage reaching millions across mainstream and industry outlets, this approach ensures one exhibition event delivers comprehensive dissemination and lasting impact.

Building on the policy advantages of the Guangdong-Hong Kong-Macao Greater Bay Area and the strengths of Guangzhou's biopharmaceutical industry, the Innovative Drugs and Medical Devices Zone at the 2026 Guangzhou Medical Expo centers on innovation as its core principle and aims for practical implementation, encompassing the entire value chain from drug and medical device R&D to clinical application and translation. We sincerely invite global innovative pharmaceutical and medical device companies, research institutions, and industry professionals to gather in Guangzhou to seize development opportunities and jointly promote high-quality growth of the healthcare sector in the Guangdong-Hong Kong-Macao Greater Bay Area!